The associations of metabolic syndrome with incident hypertension, type 2 diabetes mellitus and chronic kidney disease: a cohort study
- 133 Downloads
Metabolic syndrome (MetS) has been extensively studied for its long-term health effects, typically through conventional Cox proportional hazards regression modeling of the overall association of MetS with a single outcome. Such an approach neglects the inherent links between MetS-related disease outcomes and fails to provide sufficient insights into the impact of each component of MetS over time.
We therefore conducted a retrospective cohort study of 63,680 individuals who received health check-ups at the MJ Health Screening Center in Taiwan from 1997–2005 to study the subsequent risks of hypertension, type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) simultaneously for MetS and its components. Multivariate-adjusted hazard ratios (HRs) were calculated using Cox models for multiple failure outcomes.
At baseline, MetS was identified in 7835 participants. Over a median follow-up of 3 years, 8252, 1634, and 6714 participants developed hypertension, T2DM and CKD, respectively. The HR for MetS was 2.41 (95% CI 2.29–2.53) for hypertension, 5.17 (95% CI 4.68–5.71) for T2DM and 1.22 (95% CI 1.15–1.31) for CKD. Three MetS components showed the strongest association with each of the outcomes: elevated blood pressure with hypertension (HR = 3.62, 95% CI 3.46–3.79), raised fasting plasma glucose with T2DM (HR = 8.89, 95% CI 7.86–10.06) and elevated triglycerides with CKD (HR = 1.14, 95% CI 1.08–1.21).
MetS may help identify individuals with metabolic profiles that confer incremental risks for multiple diseases. Additionally, several components of the syndrome should be considered by clinicians, as they show stronger associations with specific diseases than MetS.
KeywordsChronic kidney disease Cohort study Hypertension Metabolic syndrome Risk factor Type 2 diabetes mellitus
This study was supported by the National Natural Science Foundation of China (grant number: 71673003) and the Interdisciplinary Fund from Peking University (grant number: BMU20160581).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
For this type of study formal consent is not required.
- 2.J. Kaur, A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. (2014). https://doi.org/10.1155/2014/943162
- 3.National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002)Google Scholar
- 12.G.L. Myers, W.G. Miller, J. Coresh, J. Fleming, N. Greenberg, T. Greene, T. Hostetter, A.S. Levey, M. Panteghini, M. Welch, J.H. Eckfeldt, Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin. Chem. 52(1), 5–18 (2006). https://doi.org/10.1373/clinchem.2005.0525144 CrossRefPubMedGoogle Scholar
- 13.WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403), 157–163 (2004). https://doi.org/10.1016/S0140-6736(03)15268-3
- 14.C.P. Wen, T.Y. Cheng, M.K. Tsai, Y.C. Chang, H.T. Chan, S.P. Tsai, P.H. Chiang, C.C. Hsu, P.K. Sung, Y.H. Hsu, S.F. Wen, All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371(9631), 2173–2182 (2008). https://doi.org/10.1016/S0140-6736(08)60952-6 CrossRefPubMedGoogle Scholar
- 15.C.P. Wen, J.P. Wai, M.K. Tsai, Y.C. Yang, T.Y. Cheng, M.C. Lee, H.T. Chan, C.K. Tsao, S.P. Tsai, X. Wu, Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 378(9798), 1244–1253 (2011). https://doi.org/10.1016/S0140-6736(11)60749-6 CrossRefPubMedGoogle Scholar
- 17.National Institute for Health and Clinical Excellence: Hypertension: clinical management of primary hypertension in adults. https://www.nice.org.uk/guidance/cg127/chapter/1-Guidance (2011). Accessed 22 Nov 2017
- 18.A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, M.W. Steffes, R.J. Hogg, R.D. Perrone, J. Lau, G. Eknoyan, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139(2), 137–147 (2003)CrossRefPubMedGoogle Scholar
- 19.A.S. Levey, P.E. de Jong, J. Coresh, M. El Nahas, B.C. Astor, K. Matsushita, R.T. Gansevoort, B.L. Kasiske, K.U. Eckardt, The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80(1), 17–28 (2011). https://doi.org/10.1038/ki.2010.483 CrossRefPubMedGoogle Scholar
- 22.B.M. Cheung, N.M. Wat, Y.B. Man, S. Tam, C.H. Cheng, G.M. Leung, J. Woo, E.D. Janus, C.P. Lau, T.H. Lam, K.S. Lam, Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). Am. J. Hypertens. 21(1), 17–22 (2008). https://doi.org/10.1038/ajh.2007.19 CrossRefPubMedGoogle Scholar
- 26.K. Dragsbaek, J.S. Neergaard, J.M. Laursen, H.B. Hansen, C. Christiansen, H. Beck-Nielsen, M.A. Karsdal, S. Brix, K. Henriksen, Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: challenging the current definition. Medicine 95(36), e4806 (2016). https://doi.org/10.1097/MD.0000000000004806 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.U.J. Jung, M.S. Choi, Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15(4), 6184–6223 (2014). https://doi.org/10.3390/ijms15046184 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.J.R. Schelling, J.R. Sedor, The metabolic syndrome as a risk factor for chronic kidney disease: more than a fat chance? J. Am. Soc. Nephrol. 15(11), 2773–2774 (2004). https://doi.org/10.1097/01.asn.0000141964.68839.bb CrossRefPubMedGoogle Scholar
- 30.H.T. Cheng, J.W. Huang, C.K. Chiang, C.J. Yen, K.Y. Hung, K.D. Wu, Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J. Clin. Endocrinol. Metab. 97(4), 1268–1276 (2012). https://doi.org/10.1210/jc.2011-2658 CrossRefPubMedGoogle Scholar
- 31.B. Spoto, A. Pisano, C. Zoccali, Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol. Renal physiol. (2016). https://doi.org/10.1152/ajprenal.00340.2016
- 32.J. Chen, D. Gu, C.S. Chen, X. Wu, L.L. Hamm, P. Muntner, V. Batuman, C.H. Lee, P.K. Whelton, J. He, Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol. Dial. Transplant. 22(4), 1100–1106 (2007). https://doi.org/10.1093/ndt/gfl759 CrossRefPubMedGoogle Scholar
- 34.O. Sidorenkov, O. Nilssen, T. Brenn, S. Martiushov, V.L. Arkhipovsky, A.M. Grjibovski, Prevalence of the metabolic syndrome and its components in Northwest Russia: the Arkhangelsk study. BMC Public Health 10, 23 (2010). https://doi.org/10.1186/1471-2458-10-23 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.J.V. van Vliet-Ostaptchouk, M.L. Nuotio, S.N. Slagter, D. Doiron, K. Fischer, L. Foco, A. Gaye, M. Gogele, M. Heier, T. Hiekkalinna, A. Joensuu, C. Newby, C. Pang, E. Partinen, E. Reischl, C. Schwienbacher, M.L. Tammesoo, M.A. Swertz, P. Burton, V. Ferretti, I. Fortier, L. Giepmans, J.R. Harris, H.L. Hillege, J. Holmen, A. Jula, J.E. Kootstra-Ros, K. Kvaloy, T.L. Holmen, S. Mannisto, A. Metspalu, K. Midthjell, M.J. Murtagh, A. Peters, P.P. Pramstaller, T. Saaristo, V. Salomaa, R.P. Stolk, M. Uusitupa, P. van der Harst, M.M. van der Klauw, M. Waldenberger, M. Perola, B.H. Wolffenbuttel, The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr. Disord. 14, 9 (2014). https://doi.org/10.1186/1472-6823-14-9 CrossRefPubMedPubMedCentralGoogle Scholar